Trial Profile
An open label pilot study of the effects of memantine administration on FDG-PET [fluoro 2 deoxy D glucose positron emission tomography] in frontotemporal dementia.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Jun 2015
Price :
$35
*
At a glance
- Drugs Memantine (Primary)
- Indications Dementia
- Focus Therapeutic Use
- 01 Jun 2012 Actual patient number is 17 according to ClinicalTrials.gov.
- 01 Jun 2012 Actual end date (Jun 2012) added as reported by ClinicalTrials.gov.
- 01 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.